3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
79
Squamous Cell Carcinoma of Head and Neck
44
Lung Neoplasms
36
Urinary Bladder Neoplasms
22
Oropharyngeal Neoplasms
22
Head and Neck Neoplasms
19
Nasopharyngeal Carcinoma
18
Carcinoma
16
Biliary Tract Neoplasms
15
Small Cell Lung Carcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Esophageal Squamous Cell Carcinoma
14
Uterine Cervical Neoplasms
13
Neoplasms
13
Neoplasm Metastasis
13
Cholangiocarcinoma
13
Ovarian Neoplasms
12
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Carcinoma, Squamous Cell
11
Laryngeal Neoplasms
10
Stomach Neoplasms
9
Mouth Neoplasms
9
Gallbladder Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Transitional Cell
8
Hypopharyngeal Neoplasms
7
Esophageal Neoplasms
7
Triple Negative Breast Neoplasms
6
Mesothelioma, Malignant
6
Interventions
darolutamide
2
pembrolizumab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Cisplatin
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled